Rein Therapeutics, Inc.

Strong clinical trial readouts can lead to surging stock prices and big follow-on public offerings (FOPOs), and in a less rocky market failed trial readouts mean that a biopharma company’s stock price

NGM Biopharmaceuticals Inc. launched the 11th biopharmaceutical initial public offering in the US this year and was the second non-alcoholic steatohepatitis (NASH) drug developer to initiate an IPO i

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

Biopharmaceutical companies launched 42 initial public offerings in the US in 2017 versus 30 in 2016 as stock values rose. But biotechnology in general endured a rough fourth quarter, raising the ques